Detailed data from the Phase III part of FRUSICA-2, the China registration study of fruquintinib in combination with sintilimab (Tyvyt, a PD-1 inhibitor) as second-line (2L) treatment for locally advanced or metastatic renal cell carcinoma (RCC), will be presented at ESMO 2025. The data provide insights into the impressive and significant magnitude of benefit observed across the primary endpoint of PFS (progression free survival), as well as secondary endpoints including ORR (objective response rate) and DoR (duration of response). The combination was tolerable, and the safety profile was
consistent with each individual treatment. This indication is currently under China NMPA review, following filing acceptance in June 2025.